menu
    • menu
    [{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2018","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2012","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Endo Pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"Collagen","graph1":"Dermatology","graph2":"Phase II","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endo Pharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Endo Pharm \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"AGN-242428","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dihomo-Gamma-Linolenate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Dihomo-Gamma-Linolenate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Dihomo-Gamma-Linolenate","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"DS107E","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"DS107E","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase II","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DS Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DS Biopharma \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allergan Aesthetics

                            U.S.A
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AGN-242428

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AGN-242428 in the Treatment of Plaque Psoriasis

                            Details : AGN-242428 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 13, 2017

                            Lead Product(s) : AGN-242428

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie CB

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cch-Aaes

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

                            Details : Cch-Aaes is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Edematous Fibrosclerotic Panniculopathy.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 15, 2022

                            Lead Product(s) : Cch-Aaes

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injectio...

                            Details : Collagenase Clostridium Histolyticum is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Edematous Fibrosclerotic Panniculopathy.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 08, 2020

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EN3835

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women

                            Details : EN3835 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cellulite.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 24, 2019

                            Lead Product(s) : EN3835

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            DS Biopharma

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            DS Biopharma

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihomo-Gamma-Linolenate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

                            Details : DS107 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 25, 2019

                            Lead Product(s) : Dihomo-Gamma-Linolenate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            DS Biopharma

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            DS Biopharma

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS107E

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe...

                            Details : DS107E is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 19, 2018

                            Lead Product(s) : DS107E

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            DS Biopharma

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            DS Biopharma

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DS107E

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Steroid Sparing Potential Study of DGLA Cream in Patients With Moderate to Severe Atopic Dermatit...

                            Details : DS107E is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 18, 2018

                            Lead Product(s) : DS107E

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Effectiveness of EN3835 in the Treatment of EFP in Women

                            Details : Collagenase Clostridium Histolyticum is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Edematous Fibrosclerotic Panniculopathy.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            November 06, 2017

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

                            Details : Collagenase Clostridium Histolyticum is a Enzyme drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Edematous Fibrosclerotic Panniculopathy.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            October 21, 2016

                            Lead Product(s) : Collagenase Clostridium Histolyticum

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            DS Biopharma

                            Ireland arrow
                            SupplySide West
                            Not Confirmed

                            DS Biopharma

                            Ireland arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dihomo-Gamma-Linolenate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

                            Details : DS107 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 06, 2016

                            Lead Product(s) : Dihomo-Gamma-Linolenate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth